Avadel Pharmaceuticals (AVDL) Cost of Revenue (2016 - 2020)
Historic Cost of Revenue for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Q2 2020 value amounting to $3.3 million.
- Avadel Pharmaceuticals' Cost of Revenue fell 930.43% to $3.3 million in Q2 2020 from the same period last year, while for Mar 2021 it was $3.3 million, marking a year-over-year decrease of 7097.03%. This contributed to the annual value of $5.7 million for FY2020, which is 5264.33% down from last year.
- Per Avadel Pharmaceuticals' latest filing, its Cost of Revenue stood at $3.3 million for Q2 2020, which was down 930.43% from $2.5 million recorded in Q1 2020.
- Avadel Pharmaceuticals' Cost of Revenue's 5-year high stood at $6.6 million during Q1 2018, with a 5-year trough of $2.4 million in Q4 2019.
- For the 5-year period, Avadel Pharmaceuticals' Cost of Revenue averaged around $3.6 million, with its median value being $3.6 million (2018).
- In the last 5 years, Avadel Pharmaceuticals' Cost of Revenue soared by 6893.9% in 2018 and then tumbled by 5045.51% in 2019.
- Avadel Pharmaceuticals' Cost of Revenue (Quarter) stood at $2.6 million in 2016, then skyrocketed by 56.23% to $4.0 million in 2017, then grew by 6.03% to $4.3 million in 2018, then plummeted by 43.76% to $2.4 million in 2019, then skyrocketed by 36.08% to $3.3 million in 2020.
- Its last three reported values are $3.3 million in Q2 2020, $2.5 million for Q1 2020, and $2.4 million during Q4 2019.